Sonoma Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

3. Summary of Significant Accounting Policies (Details-Antidilutive shares)

3. Summary of Significant Accounting Policies (Details-Antidilutive shares)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Total securities excluded from computation of basic net loss per share	10,618,000	2,532,000
Stock Options
Total securities excluded from computation of basic net loss per share	2,877,000	1,122,000
Warrants
Total securities excluded from computation of basic net loss per share	7,741,000	1,410,000

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References + Details